scispace - formally typeset
N

Natalija Novak

Researcher at University Hospital Bonn

Publications -  56
Citations -  2081

Natalija Novak is an academic researcher from University Hospital Bonn. The author has contributed to research in topics: Atopic dermatitis & Vaccination. The author has an hindex of 17, co-authored 56 publications receiving 1415 citations. Previous affiliations of Natalija Novak include University of Bonn.

Papers
More filters
Journal ArticleDOI

Shared genetic origin of asthma, hay fever and eczema elucidates allergic disease biology

Manuel A. R. Ferreira, +73 more
- 30 Oct 2017 - 
TL;DR: A genome-wide association study of a broad allergic disease phenotype that considers the presence of any one of these three diseases identified 136 independent risk variants, including 73 not previously reported, which implicate 132 nearby genes in allergic disease pathophysiology.
Journal ArticleDOI

Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis.

Lavinia Paternoster, +116 more
- 01 Feb 2012 - 
TL;DR: A genome-wide association meta-analysis of affected individuals and controls and the ten most strongly associated new susceptibility loci examined underline the importance of both epidermal barrier function and immune dysregulation in atopic dermatitis pathogenesis.

Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis

Lavinia Paternoster, +116 more
TL;DR: This paper conducted a genome-wide association meta-analysis of 5,606 affected individuals and 20,565 controls from 16 population-based cohorts and then examined the ten most strongly associated new susceptibility loci in an additional 5,419 affected individuals from 14 studies.
Journal ArticleDOI

Allergic reactions to the first COVID-19 vaccine: a potential role of Polyethylene glycol?

TL;DR: The COVID-19 vaccine developed by Pfizer and BioNTech was approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom on December 2nd 2020, making it the first regulator agency in the world to approve a vaccine to prevent coronavirus disease.